Inventor · disambiguated record
Charlotte Albaek Thrue
Also filed as: THRUE CHARLOTTE A · THRUE CHARLOTTE ALBAEK
19 granted patents·11 pending applications·686 citations·filing 2003–2018
95Inventor score
Files withSANTARIS PHARMA AS11ROCHE INNOVATION CT COPENHAGEN AS9ENZON PHARMACEUTICALS INC4HANSEN BO2CHRISTENSEN SIGNE M1
Top patents by PatentIndex Score
30 records- 0198US7589190B2Potent LNA oligonucleotides for the inhibition of HIF-1A expressionSANTARIS PHARMA AS·Filed 2005·Granted Sep 15, 2009·129 cites·8 claims
- 0297US9708614B2Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2016·Granted Jul 18, 2017·28 cites·36 claims
- 0397US9428534B2Antisense designSANTARIS PHARMA AS·Filed 2013·Granted Aug 30, 2016·46 cites·78 claims
- 0497US7687617B2Oligonucleotides with alternating segments of locked and non-locked nucleotidesSANTARIS PHARMA AS·Filed 2003·Granted Mar 30, 2010·207 cites·26 claims
- 0595US7741309B2Oligomeric compounds for the modulation of survivin expressionENZON PHARMACEUTICALS·Filed 2009·Granted Jun 22, 2010·120 cites·12 claims
- 0694US7622453B2Oligomeric compounds for the modulation of Bcl-2SANTARIS PHARMA AS·Filed 2004·Granted Nov 24, 2009·114 cites·57 claims
- 0792US9994850B2Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Jun 12, 2018·4 cites·19 claims
- 0889US9045518B2Amino-LNA, thio-LNA and alpha-L-oxy-LNCHRISTENSEN SIGNE M·Filed 2003·Granted Jun 2, 2015·19 cites·19 claims
- 0987US8026355B2Oligomeric compounds for the modulation of survivin expressionSANTARIS PHARMA AS·Filed 2010·Granted Sep 27, 2011·10 cites·9 claims
- 1081US8785617B2Oligomeric compounds for the modulation of HIF-1A expressionENZON PHARMACEUTICALS INC·Filed 2012·Granted Jul 22, 2014·4 cites·19 claims
- 1178US7939507B2Potent LNA oligonucleotides for the inhibition of HIF-1a expressionENZON PHARMACEUTICALS INC·Filed 2009·Granted May 10, 2011·2 cites·5 claims
- 1275US9447138B2Potent LNA oligonucleotides for the inhibition of HIF-1a expressionSANTARIS PHARMA AS·Filed 2013·Granted Sep 20, 2016·1 cites·4 claims
- 1373US7846911B2Oligomeric compounds for the modulation of HIF-1alpha expressionENZON PHARMACEUTICALS INC·Filed 2009·Granted Dec 7, 2010·1 cites·9 claims
- 1472US2018237777A1Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Application pending·0 cites
- 1571US9951333B2Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Apr 24, 2018·0 cites·30 claims
- 1671US9890383B2Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Feb 13, 2018·0 cites·30 claims
- 1770US2014128591A1Antisense designSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 1870US2018237778A1Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Application pending·0 cites
- 1968US2014194614A1Amino-lna, thio-lna and alpha-l-oxy-lnSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 2066US2014128586A1Amino-lna, thio-lna and alpha-l-oxy-lnSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 2166US2016168575A1Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2015·Application pending·0 cites
- 2265US8410071B2Potent LNA oligonucleotides for the inhibition of HIF-1A expressionWESTERGAARD MAJKEN·Filed 2011·Granted Apr 2, 2013·1 cites·9 claims
- 2365US2016168576A1Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2015·Application pending·0 cites
- 2460US9938527B2Potent LNA oligonucleotides for the inhibition of HIF-1A expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2016·Granted Apr 10, 2018·0 cites·12 claims
- 2558US8357670B2Oligomeric compounds for the modulation of HIF-1A expressionENZON PHARMACEUTICALS INC·Filed 2012·Granted Jan 22, 2013·0 cites·9 claims
- 2649US2004248840A1Oligomeric compounds for the modulation of ras expressionSANTARIS PHARMA AS·Filed 2004·Application pending·0 cites
- 2748US8207140B2Oligomeric compounds for the modulation of HIF-1α expressionTHRUE CHARLOTTE ALBAEK·Filed 2010·Granted Jun 26, 2012·0 cites·9 claims
- 2846US2012088907A1Oligomeric compounds for the modulation of survivin expressionHANSEN BO·Filed 2011·Application pending·0 cites
- 2946US2004241717A1Oligomeric compounds for the modulation of thioredoxin expressionSANTARIS PHARMA AS·Filed 2004·Application pending·0 cites
- 3045US2008188432A1Oligomeric compounds for the modulation ras expressionHANSEN BO·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Charlotte Albaek Thrue files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →